SSP Of Japan Now 93 Percent Owned By German Drug Maker
This article was originally published in PharmAsia News
Executive Summary
Japan's SSP has become at least 93 percent owned by German drug maker Boehringer Ingelheim, almost enough to make SSP part of a holding company of the investor. SSP is Japan's third-largest producer of over-the-counter drugs, specializing in those considered easy to take. Boehringer Ingelheim expects to increase its stake in SSP to nearly 94 percent, at which point the German firm would take SSP off the stock market. (Click here for more - a subscription may be required
You may also be interested in...
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.